Today's Date: June 2, 2023
Bijou Ikli named new CEO by Florida Assisted Living Association   •   BURGERFI DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Bu   •   SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Funko, Inc. with Losses of $100,000 to Contact the Firm   •   Hilton brings back exclusive pop-up hotel experience 'Hilton on the Green' to the 2023 RBC Canadian Open   •   Rapid Dose Announces Proposed Private Placement Financing   •   The Assembly of First Nations and the Government of Canada announce updates to school design standards for schools on-reserve   •   FNKO INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Funko, Inc. Investors with Substantial Losses Have Opp   •   56 Trilogy Health Services Communities Earn 2023 AHCA/NCAL Bronze National Quality Award   •   Statement from Minister Hutchings on progress in support of rural Canadians   •   SENTINELONE ALERT: Bragar Eagel & Squire, P.C. is Investigating SentinelOne, Inc. on Behalf of SentinelOne Stockholders and   •   CURE HOSTS "AI FOR GOOD" SUPER SESSION TO MAKE SENSE OF BIG DATA AND HIGH TECH AT 2023 BIO INTERNATIONAL CONVENTION ON JUNE 5   •   INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of SentinelOne, Inc. (S) on Behalf of Investors   •   ETHNIC CONFLICTS IN NIGERIA: UNMASKING THE PUPPET MASTERS   •   HESAI DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Hesai   •   San Francisco Pride Announces Headliners Hayley Kiyoko and Princess Nokia for 53rd Annual SF Pride Parade & Celebration Feat   •   INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of DZS Inc. (DZSI) on Behalf of Investors   •   Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of LivePerson, Inc. (LPSN) Investors   •   Promoting Diversity and Equity in Cancer Research, Women Leaders in Oncology® and Vaniam Group Announce Recipients of 2023 Y   •   Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice   •   UNice Celebrates LGBTQ Pride Month
Bookmark and Share

Pharmaron’s Liverpool UK Gene Therapy CDMO Commences Major Site Expansion Following UK Government Grant to Support £

BEIJING , March 29 /Businesswire/ - Pharmaron Beijing Co., Limited (Stock Code: 300759.SZ/3759.HK) (“Pharmaron”) announced today that their Liverpool, UK based Gene Therapy CDMO has received a prestigious grant from the UK Government’s Life Sciences Innovation Manufacturing Fund (LSMIF) to expand their viral vector and DNA manufacturing facilities for more than 8,000 sqM.

This major expansion project will provide a four-fold increase in gene therapy process development and analytical capacity accommodating viral vector, DNA and RNA drug substance, plus drug product formulation. The expansion includes 3,500 sqM for future commercial scale GMP capacity.

The resulting facility will greatly enhance the scale and scope of Pharmaron’s services to vaccine, cell and gene therapy customers and allows Pharmaron to continue expanding its scientific team at Liverpool. The total investment in capital and people for this expansion is estimated to be in the region of £151M.

Pharmaron acquired the established Liverpool CGT facility from AbbVie in 2021 and has rapidly added customers with 29 gene therapy and vaccine projects running through 2022. The expansion will allow this pace of growth to continue beyond the capacity of the existing state-of-the-art development and GMP facility, which will remain fully operational during, and after, the expansion project.

Construction activities commenced in January 2023 and facility handover is expected in 2024.

Dr. Boliang Lou, Chairman and Chief Executive Officer of Pharmaron, commented, “I am delighted that we have been awarded this funding from the UK Government. Securing this grant demonstrates UK Government’s support and trust in Pharmaron to continuously expand our state-of-the-art infrastructure and top-notch scientific team at Liverpool to serve the gene therapy and vaccine development community in UK and abroad. We look forward to our new facilities coming online to support our partners that are delivering innovative, life changing medicines for patients in 2025.”

About Pharmaron

Pharmaron (Stock Code: 300759.SZ/3759.HK) is a premier R&D service provider for the life sciences industry. Founded in 2004, Pharmaron has invested in its people and facilities, and established a broad spectrum of research, development and manufacturing service capabilities throughout the entire drug discovery, preclinical and clinical development process across multiple therapeutic modalities, including small molecules, biologics and cell & gene therapy products. With over 19,000 employees, and operations in China, UK and US, Pharmaron has an excellent track record in the delivery of R&D solutions to its partners globally.

Pharmaron’s GT CDMO operates out of state-of-the-art facilities in Liverpool, UK that were previously Allergan’s global centre of excellence for biologic drug substance development and divested by AbbVie in May 2021 following the acquisition of Allergan. Pharmaron has since launched a CDMO business from the site and continued to invest in world class innovation in viral vector and gene therapy analytical and process technology to support partners around the world.

Recent Gene Therapy CDMO partnership announcements:

  1. Collaboration with Vaccitech plc (NASDAQ: VACC) to support its novel T cell immunotherapeutics and vaccines development and manufacturing;
  2. Strategic partnership for the Development and Clinical Manufacture of a Gene Therapy for the treatment of Geographic Atrophy with Complement Therapeutics Ltd (CTx).


STORY TAGS: Ireland, Asia Pacific, United Kingdom, Europe, China, Health, Genetics, Other Health, General Health, Pharmaceutical, Biotechnology, Funding, Product/Service,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News